Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Abeer N. Abouyabis"'
Publikováno v:
Journal of Hematology
Coronavirus disease 2019 (COVID-19) has been associated with a spectrum of reported hematological complications ranging from immune cytopenias to thromboembolic manifestations of coagulopathy. Moreover, there have been documented cases of hemolytic a
Autor:
Chloe S. Lalonde, Tony Z. Zhuang, Amalia A. Aldredge, Max W. Adelman, Abeer N. AbouYabis, Morgan L. McLemore, Sara C. Auld
Publikováno v:
Cancer Research. 82:444-444
Background: Immune reconstitution inflammatory syndrome (IRIS) is a rapid inflammatory response with immune recovery, most commonly observed following antiretroviral therapy initiation in people with HIV and underlying opportunistic infections. To da
Publikováno v:
Blood
Introduction: The Grady Comprehensive Sickle Cell (SC) center is the largest adult sickle cell center in the United States (US) and has the first 24/7 acute care unit for management of sickle cell vaso-occlusive events (VOE). In 2019, the center prov
Autor:
Mary Jo Lechowicz, Rajini Sinha, Pareen J. Shenoy, Abeer N. AbouYabis, Christopher R. Flowers
Publikováno v:
ISRN Hematology
Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall
Publikováno v:
Clinical Leukemia. 1:46-56
Treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. A purine nucleoside analogue, alone or combined with other drugs, including monoclonal antibodies, is becoming the preferred first-line regimen for patients with CLL. B
Publikováno v:
Expert opinion on biological therapy. 11(1)
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin's lymphomas in which conventional chemotherapy has been characterized by poor outcomes when compared with most aggressive B-cell lymphomas. Autologous, and to a lesser extent
Publikováno v:
Leukemialymphoma. 49(11)
Peripheral T-cell lymphomas (PTCL) represent a small subgroup of non-Hodgkin lymphomas historically difficult to diagnose. We conducted a comprehensive assessment of 3287 PTCL cases diagnosed from 1992 to 2005 in 13 Surveillance, Epidemiology and End
Publikováno v:
Blood. 110:3452-3452
Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas (NHL) for which CHOP-type chemotherapy remains the standard despite its suboptimal results, especially when compared to its outcome in B-cell N
Autor:
M.J. Lechowicz, Leonard T. Heffner, Silvana Z. Bucur, Abeer N. Abouyabis, Christopher R. Flowers, Karen P. Mann, Elliot F. Winton
Publikováno v:
Blood. 108:4689-4689
Background: Compared to B-cell lymphomas, peripheral T-cell non-Hodgkin lymphomas (PTCL) represent a subtype that more frequently involve extranodal sites and worse relapse free survival (RFS) and overall survival (OS) with and without risk stratific